Evidence map›Paper›PMID 39050564›Full record

ArticleFrontiers in endocrinology2024

Healthcare professionals' perspectives towards the digitalisation of paediatric growth hormone therapies: expert panels in Italy and Korea.

Octavio Rivera Romero, Hyun Wook Chae, Maria Felicia Faienza, Edoardo Vergani, Chong Kun Cheon, Raffaella Di Mase, Francesco Frasca, Hae Sang Lee, Claudia Giavoli, Jihyun Kim and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Octavio Rivera RomeroElectronic Technology Department, Universidad de Sevilla, Seville, Spain.
Hyun Wook ChaeDepartment of Pediatrics, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Maria Felicia FaienzaUnit of Endocrinology and Rare Endocrine Diseases, Pediatric Hospital Giovanni XXIII, Bari, Italy.
Edoardo VerganiDepartment of Translational Medicine and Surgery, Agostino Gemelli Polyclinic Foundation, IRCCS - Catholic University of the Sacred Heart, Rome, Italy.
Chong Kun CheonDepartment of Pediatrics, Pusan National University Children's Hospital, Yangsan, Republic of Korea.
Raffaella Di MasePediatric Endocrinology Unit, University Hospital "Federico II", Naples, Italy.
Francesco FrascaEndocrinology Section, Department of Clinical and Experimental Medicine, Garibaldi Nesima Hospital, University of Catania, Catania, Italy.
Hae Sang LeeDepartment of Pediatrics, Ajou University School of Medicine, Suwon, Republic of Korea.
Claudia GiavoliEndocrinology Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy.
Jihyun KimDepartment of Pediatrics, Dongguk University Ilsan Hospital, Goyang, Republic of Korea.
Antonella KlainPediatric Endocrinology Unit, Santobono Pausilipon Children's Hospital, Naples, Italy.
Jung Eun MoonDepartment of Pediatrics, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Republic of Korea.
Maria Laura IezziPediatric Department, San Salvatore Hospital, University of L'Aquila, L'Aquila, Italy.
James YehMerck Ltd., Seoul, South Korea, an affiliate of Merck KGaA, Darmstadt, Germany.
Antonio AversaSection of Endocrinology, Department of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro, Catanzaro, Italy.
Young-Jun RhieDepartment of Pediatrics, Korea University College of Medicine, Seoul, Republic of Korea.
Ekaterina KoledovaGlobal Medical Affairs, Cardiometabolic and Endocrinology, Merck Healthcare KGaA, Darmstadt, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: To analyse the perspectives of healthcare professionals (HCPs) regarding the acceptance of digital health solutions for growth hormone (GH) deficiency care. This study identified factors impacting HCPs' intent to use and recommend digital solutions supporting recombinant-human growth hormone (r-hGH) therapy in Italy and Korea with a use case of connected drug delivery system (Aluetta Methods: Participatory workshops were conducted in Rome, Italy, and Seoul, Korea, to collect the perspectives of 22 HCPs on various predefined topics. HCPs were divided into two teams, each moderated by a facilitator. The workshops progressed in five phases: introduction of the project and experts, capturing views on the current context of digitalisation, perceived usefulness and ease of use of Aluetta Results: HCPs from both Italy and Korea perceived Aluetta Conclusion: HCPs' perspectives on the digitalisation in paediatric GH therapies suggested that digital solutions enable automatic, real-time injection data transmission to support adherence monitoring and evidence-based therapy, strengthen HCP-patient relationships, and empower patients throughout the GH treatment process.

Indexed as

Health PersonnelHuman Growth HormoneAttitude of Health PersonnelChildDrug Delivery SystemsFemaleGrowth DisordersHumansItalyMaleRepublic of KoreaTelemedicineHuman Growth Hormoneadherence monitoringAluetta®Smartdot™connected devicedigital healthhealthcare digitalisationrecombinant human growth hormone

Identifiers

PMID39050564
PMCPMC11266127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.